Revance Therapeutics
Manufacturing · Tennessee, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1222 Demonbreun St Fl 20, Nashville, Ten...Phone Number
(877) 373-8669Website
www.revance.comRevenue
$251.2 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
8
1
2
2
2
2
About Revance Therapeutics
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark,...Explore more
Revance Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Revance Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Revance Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Revance Therapeutics recently announced quarterly report
Check if Revance Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Revance Therapeutics launches new products
Funding: Get notified immidiatlly once Revance Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if Revance Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Revance Therapeutics
Revance Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Revance Therapeutics
Find more new buyers
Compare Similar Companies to Revance Therapeutics
Compare insights from companies similar to Revance Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Revance Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Revance Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Revance Therapeutics.
Revance Therapeutics financials insights
Gather financial insights about Revance Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$1.8M
2004
Series B
$13M
2007
Series C
$43.2M
2011
Series D
$45M
2013
Series E
$33M
2014
Stock Offering
$96M
2022
Debt
$300M
Revance Therapeutics Tech Stack
A closer look at the technologies used by Revance Therapeutics
Most Recent Scoops
Event
Retail/Store Systems, Product Marketing, Events, Sales, Store Operations, Logistics / Supply Chain, Field /Outside Sales, Field Marketing
Hiring Plans
Revance Therapeutics has more open roles in Marketing than it has had at any time in the past 12 months. Technologies mentioned include: Salesforce, HubSpot, and Canva. Areas of expertise include: Marketing.
Hiring Plans
Open Position
Open Position
Hiring Plans
Hiring Plans
Revance Therapeutics News & Media
Revance Announces Julianne Hough as the Celebrity Brand Partner for DAXXIFY® Brand Injectable
Discover the DAXXIFY Difference: The first and only frown line treatment with a peptide formulation.*1 NASHVILLE, Tenn., June 23, 2026 /PRNewswire/ -- Revance, a global aesthetics, regenerative and consumer skincare company, is proud to announce world renowned dancer, actress and host...Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]Revance Distributed Over 1 Million SkinPen® Treatment Kits to Customers Since January 2025
Milestone underscores rapid growth of microneedling and strong demand for SkinPen NASHVILLE, Tenn., March 31, 2026 /PRNewswire/ -- Revance, a fast-growing global aesthetics and skincare company, announced today that it has distributed over one million SkinPen treatment kits nationwide...Revance Presents Award-Winning Aesthetics and Skincare Portfolio at 2026 AAD Annual Meeting
NASHVILLE, Tenn., March 25, 2026 /PRNewswire/ -- Revance, a fast-growing global aesthetics, regenerative and consumer skincare company, will showcase the latest innovations and new indications across its extensive portfolio at the American Academy of Dermatology (AAD) Annual Meeting,...
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Revance Therapeutics
Sign Up For FreeTo access detailed company insights
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) li... Read More
